Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kyowa Kirin Officially Announces Launch of Japan’s 1st Rituxan Biosimilar on Jan. 18
Kyowa Hakko Kirin officially announced on January 17 that it will release Japan’s first biosimilar version of Rituxan (rituximab), manufactured by Sandoz, on January 18, sticking to the planned launch date despite the filing of a patent infringement suit by…
To read the full story
Related Article
- Japan’s 1st Rituxan Biosimilar Boasts 13% Share: Sandoz Country Head
June 28, 2018
- Japan’s 1st Rituxan Biosimilar to Hit Shelves as Scheduled despite Patent Suit Filed
January 16, 2018
- Genentech Seeks to Block Rituxan Biosimilar Launch in Japan
January 10, 2018
- Japan’s 1st Rituxan Biosimilar to Arrive Soon, Sandoz Confident on Market Acquisition
November 29, 2017
- Japan Approves 1st Rituxan Biosimilar from Sandoz
September 28, 2017
BUSINESS
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
- FDA Puts Regenxbio’s MPS II Gene Therapy Back on Clinical Hold
August 25, 2026
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
- Daiichi Sankyo Taps Ken Keller as New Commercial Chief in Global Revamp
August 25, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…